Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,825 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06635785RecruitingPhase 1/Phase 2
AI-081 for advanced solid tumors
This trial tests a new drug called AI-081 that targets the immune system and tumor blood vessels. It is for people with advanced solid tumors who have not responded to other treatments or cannot take them.
Birmingham, AlabamaAges 18 years+ - NCT07516444Recruiting
Tricuspid valve replacement using a new catheter device
This trial tests a new device that replaces a leaky tricuspid valve (a heart valve) without open-heart surgery. If your tricuspid valve isn't working well and medicines haven't helped enough, this procedure might improve your heart function and symptoms.
Minneapolis, MinnesotaAges 18 years+ - NCT06303505RecruitingPhase 1/Phase 2
Study of TUB-040 for ovarian and lung cancer
This study tests a new drug called TUB-040 that targets a protein (NaPi2b) found on some ovarian and lung cancer cells. It is for people whose cancer has stopped responding to standard treatments and who have not had certain lung problems in the past.
Birmingham, AlabamaAges 18 years+ - NCT05929807Enrolling by invitationPhase 2/Phase 3
Weekly injection study for children with achondroplasia
This trial looks at how safe and effective weekly under-the-skin (subcutaneous) TransCon CNP is for children and teens with achondroplasia over the long term. You may be considered if your child has already finished a previous TransCon CNP study and can follow weekly injection and follow-up visits.
Little Rock, ArkansasAges 3–15 - NCT06688435RecruitingPhase 1
Immune cell therapy for hard-to-treat myasthenia gravis
This trial tests a new immune cell treatment (CAR T-cells) for people with generalized myasthenia gravis that has not improved with standard treatments. It aims to reduce symptoms by targeting and calming the immune system's attack on muscles.
JinanAges 18–65 - NCT04707300RecruitingPhase 1/Phase 2
HTLP injection to speed immune recovery after cord blood transplant
This Phase 1/2 study tests whether a specific immune-cell “starter” injection (HTLP) can help adults rebuild their immune system faster after an umbilical cord blood transplant for blood cancers. It mainly focuses on safety and whether immune recovery improves.
ParisAges 18–66 - NCT06897930RecruitingPhase 1/Phase 2
Testing a new drug for adults with lupus
This trial tests an investigational drug called AZD0120 in adults with lupus that hasn't improved with standard treatments. The goal is to see if it's safe and works well for people with lupus-related organ problems.
San Francisco, CaliforniaAges 18–70 - NCT07758634RecruitingPhase 1/Phase 2
Study of an experimental treatment for high blood pressure
This trial tests a new treatment called CTX340 for high blood pressure that is hard to control even with multiple medications. The study aims to see if it is safe and effective.
Port Orange, FloridaAges 18–75 - NCT06615206Recruiting
First CRISPR RNA therapy for MECP2 duplication syndrome
This trial tests a new CRISPR therapy that edits RNA to treat a rare genetic condition called MECP2 duplication syndrome (MDS). It is for boys aged 2 to 18 who have stable seizures and no other major health problems, with the goal of improving symptoms and safety.
Beijing, Beijing MunicipalityAges 2–18 - NCT06677229RecruitingPhase 1/Phase 2
Safety and effectiveness of TZ-161 for spinal cord injury
This trial tests a new medicine called TZ-161 in people who have recently had a spinal cord injury in the chest area. The goal is to see if it is safe and can help improve movement.
CórdobaAges 18–65 - NCT04818203RecruitingPhase 1/Phase 2
Autologous fibroblast injections for crow’s feet wrinkles
This study tests a safety and effectiveness approach for reducing crow’s feet (wrinkles at the outer corners of the eyes) using cells made from your own skin. You may be asked to stop other wrinkle treatments and have blood tests and injections at a specific skin area.
SeoulAges 19 years+ - NCT06824987RecruitingPhase 2
Study of AZD2373 for APOL1-related kidney disease
This trial tests an experimental drug (AZD2373) for people with kidney disease caused by APOL1 gene changes. It aims to find the safest and most effective dose to slow kidney damage.
Alabaster, AlabamaAges 18–65 - NCT06820424RecruitingEarly Phase 1
CDH17-targeted CAR-T cells for advanced solid tumors
This trial tests a new type of immunotherapy that uses your own modified immune cells (CAR-T cells) to find and attack cancer cells that carry a specific marker called CDH17. It is for adults with advanced solid tumors that have CDH17 and who have run out of standard treatment options.
Kunming, YunnanAges 18–75 - NCT07229638RecruitingPhase 1/Phase 2
Study of SHR-9839 with other treatments for solid tumors
This study tests a new drug called SHR-9839 given under the skin, combined with other anti-cancer treatments, for people with solid tumors. The goal is to see if it is safe and effective.
Nanjing, JiangsuAges 18–70 - NCT06004063Recruiting
Liquid nutrition vs. usual diet in stem cell transplant patients
This study tests whether giving liquid nutrition through a feeding tube during stem cell transplant is better than the usual diet. The goal is to see if it is safe and can help patients feel better during recovery.
Houston, TexasAges 18 years+ - NCT07387068RecruitingPhase 1
Testing GEN1079 for advanced solid tumors
This trial tests an experimental drug called GEN1079 for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if it's safe and if it helps shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT06321198Recruiting
Modified stem cells for severe graft-versus-host disease
This trial tests a new type of stem cell therapy (iMSC) for people with steroid-resistant acute graft-versus-host disease (aGVHD), a serious complication after a stem cell transplant. The goal is to see if it's safe and might help control the disease.
Hefei, AnhuiAges 4–70 - NCT07491458RecruitingPhase 2
Study of HU6 versus placebo for adults with MASH
This trial tests if HU6 is safe and effective for people with MASH, a type of fatty liver disease. You will either receive HU6 or a placebo to see how it affects your liver health.
Chandler, ArizonaAges 30 years+ - NCT07044128Recruiting
Testing a new electronic stethoscope for heart murmur checks
This study is testing a new electronic stethoscope (called Keikku) to see if it works well and is safe for checking heart murmurs in children and adults who are not in an emergency situation. If it works, it could give doctors a better tool for evaluating heart sounds.
LimaAges Up to 99 years - NCT07557589Recruiting
Radiofrequency Treatment for Pilonidal Disease Safety and Effectiveness
This study tests a radiofrequency (heat-based) treatment to safely and effectively treat pilonidal sinus disease—a condition where an infected cavity forms near the tailbone. Researchers will check if this non-surgical approach reduces infection, works well, and keeps patients satisfied over 6 months.
DaxAges 18 years+ - NCT07055594RecruitingPhase 1/Phase 2
Study of SOA101 for advanced solid tumors
This trial tests a new drug called SOA101 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug is safe and if it can help shrink tumors.
TaichungAges 18 years+ - NCT06071767RecruitingPhase 1/Phase 2
Immune therapy trial for early-treated HIV
This study tests whether a combination of three immune therapies can help control HIV without daily medication. You may qualify if you started HIV treatment very early and have had a suppressed viral load for at least a year.
San Diego, CaliforniaAges 18 years+ - NCT06474442RecruitingPhase 2
BD111 gene therapy for herpes simplex virus eye infection
This trial tests a new gene therapy called BD111 for people with a herpes simplex virus infection in the cornea (the clear front part of the eye). It aims to see if the treatment is safe and can help clear the virus, possibly improving vision.
Wenzhou, ZhejiangAges 18–70 - NCT06618313Recruiting
Testing JCXH-213 for B-cell lymphoma that returned or didn't respond
This trial tests a new treatment called JCXH-213 for people with B-cell non-Hodgkin lymphoma that came back or didn't get better after previous treatment. It aims to see if the treatment is safe and works against the cancer.
BeijingAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,825 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.